These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 7697603

  • 1. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS.
    Cancer; 1995 Apr 15; 75(8):2123-31. PubMed ID: 7697603
    [Abstract] [Full Text] [Related]

  • 2. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL.
    Hum Pathol; 2001 May 15; 32(5):487-93. PubMed ID: 11381366
    [Abstract] [Full Text] [Related]

  • 3. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003 May 15; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 4. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
    Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP.
    Histopathology; 1998 Dec 15; 33(6):531-6. PubMed ID: 9870147
    [Abstract] [Full Text] [Related]

  • 5. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T, Shousha S.
    Histopathology; 2003 May 15; 42(5):440-7. PubMed ID: 12713620
    [Abstract] [Full Text] [Related]

  • 6. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
    Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Baldetorp B, Linden T, Hansen B, Andersen J.
    Breast Cancer Res Treat; 2000 Apr 15; 60(3):219-26. PubMed ID: 10930109
    [Abstract] [Full Text] [Related]

  • 7. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L, Kerkvliet N, Doig G, O'Malley FP.
    Hum Pathol; 1997 Aug 15; 28(8):974-9. PubMed ID: 9269835
    [Abstract] [Full Text] [Related]

  • 8. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Aug 15; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 9. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW, Ellis IO.
    Mod Pathol; 1994 Feb 15; 7(2):257-62. PubMed ID: 7911998
    [Abstract] [Full Text] [Related]

  • 10. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
    Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C.
    Am J Clin Pathol; 2001 May 15; 115(5):709-18. PubMed ID: 11345835
    [Abstract] [Full Text] [Related]

  • 11. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H.
    Jpn J Cancer Res; 2000 Nov 15; 91(11):1169-76. PubMed ID: 11092983
    [Abstract] [Full Text] [Related]

  • 12. Is there a low-grade precursor pathway in breast cancer?
    King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.
    Ann Surg Oncol; 2012 Apr 15; 19(4):1115-21. PubMed ID: 21935747
    [Abstract] [Full Text] [Related]

  • 13. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
    Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A.
    Mod Pathol; 1997 Nov 15; 10(11):1088-92. PubMed ID: 9388058
    [Abstract] [Full Text] [Related]

  • 14. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
    Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R, Reiner A.
    Eur J Cancer; 1997 Jan 15; 33(1):39-44. PubMed ID: 9071897
    [Abstract] [Full Text] [Related]

  • 15. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C.
    Histopathology; 2005 May 15; 46(5):561-8. PubMed ID: 15842638
    [Abstract] [Full Text] [Related]

  • 16. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I.
    Cancer Detect Prev; 1998 May 15; 22(4):313-8. PubMed ID: 9674874
    [Abstract] [Full Text] [Related]

  • 17. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.
    Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO.
    Hum Pathol; 1993 May 15; 24(5):463-8. PubMed ID: 8098318
    [Abstract] [Full Text] [Related]

  • 18. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
    Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, Elston CW, Blamey RW, Ellis IO.
    Br J Cancer; 1993 Jul 15; 68(1):156-61. PubMed ID: 8100443
    [Abstract] [Full Text] [Related]

  • 19. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S, Sasano H.
    Anticancer Res; 2000 Jul 15; 20(2B):1101-8. PubMed ID: 10810403
    [Abstract] [Full Text] [Related]

  • 20. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.
    Pathol Int; 2003 Jul 15; 53(7):422-8. PubMed ID: 12828606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.